Table 2.
Pharmacovigilance mentions in PMI FY 2009 MOPs and in Global Fund Round 8 - Malaria proposals
| PMI FY 2009 Countries (15 total) | No. of responses (% of total) | Global Fund Round 8 Countries (26 total) | No. of responses (% of total) | |
|---|---|---|---|---|
| Country has a Pharmacovigilance Programme mentioned in MOP or Global Fund proposal | ||||
| Yes | KEN, MDG, MWI, SEN, | 4 (27%) | BFA, CAF, COL, COM, CIV, ETH, GHA, NGA, PNG, UZB, ZBR, ZWE | 12 (46%) |
| No | AGO, ETH, GHA, LBR | 4 (27%) | AFG, BOL, BRA, COG, ECU, COD, HTI, KGZ, RWA, TJK, TZA, | 11 (42%) |
| Initial Phase of Development | BEN, MLI, MOZ, RWA, UGA | 5 (33%) | ||
| No mention in proposal | TZA, ZMB | 2 (13%) | IDN, KOR, SWZ, | 3 (12%) |
| Total Respondents | 15 (100%) | 26 (100%) | ||
| A section is dedicated to pharmacovigilance in the MOP or Global Fund proposal | ||||
| Yes | LBR, MDG, MWI, MLI, MOZ, RWA, SEN, UGA | 8 (53%) | COL, COM, COG, COD, ETH, GHA, NGA, ZBR | 8 (31%) |
| No | AGO, BEN, ETH, GHA, KEN, TZA, ZMB | 7 (47%) | AFG, BOL, BRA, BFA, CAF, CIV, ECU, HTI, IDN, KOR, KGZ, PNG, RWA, SWZ, TJK, TZA, UZB, ZWE | 18 (69%) |
| Total Respondents | 15 (100%) | 26 (100%) | ||
| A pregnancy registry is mentioned in the MOP or Global Fund proposal | ||||
| Yes | UGA | 1 (7%) | None | 0 (0%) |
| No/Not mentioned in proposal | AGO, BEN, ETH, GHA, KEN, LBR, MDG, MWI, MLI, MOZ, RWA, SEN, TZA, ZMB | 14 (93%) | All | 26 (100%) |
| Total Respondents | 15 (100%) | 26 (100%) | ||
| The country requested funds in its MOP or Global Fund proposal for pharmacovigilance activities: | ||||
| Yes | GHA, MDG, MWI, MLI, MOZ, RWA, UGA | 7 (47%) | CAF, COL, COG, CIV, NGA, SWZ, ZBR | 7 (27%) |
| No | AGO, BEN, ETH, KEN, LBR, SEN, TZA, ZMB | 8 (53%) | AFG, BOL, BRA, BFA, COM, DR of Congo, ECU, ETH, GHA, HTI, IDN, KOR, KGZ, PNG, RWA, TJK, TZA, UZB, ZWE | 19 (73%) |
| Total Respondents | 15 (100%) | 26 (100%) | ||
| Type of Pharmacovigilance surveillance mentioned in MOP or Global Fund proposal | ||||
| Passive only | LBR, MWI, UGA | 3 (20%) | BFA, CAF, COL, COM, COG, CIV, ETH, NGA, PNG, RWA, UZB, ZBR, ZWE | 13 (50%) |
| Active only | 0 (0%) | 0 (0%) | ||
| Both passive and active | MDG, MLI, RWA | 3 (20%) | GHA | 1 (4%) |
| None mentioned | AGO, BEN, ETH, GHA, KEN, MOZ, SEN, TZA, ZMB | 9 (60%) | AFG, BOL, BRA, COD, ECU, HTI, IDN, KOR, KGZ, SWZ, TJK, TZA | 12 (46%) |
| Total Respondents | 15 (100%) | 26 (100%) | ||
| A national agency in charge of Pharmacovigilance activities is mentioned in MOP or Global Fund proposal | ||||
| Yes | GHA, KEN, LBR, MDG, MWI, MLI, MOZ, RWA, SEN, UGA, ZMB | 11 (73%) | AFG, BOL, BRA, BFA, CAF, COL, COM, COG, CIV, COD, ETH, GHA, HTI, IDN, KOR, KGZ, NGA, PNG, SWZ, TJK, UZB, ZWE | 23 (88%) |
| No/Not mentioned in proposal | AGO, BEN, ETH, TZA | 4 (27%) | ECU, RWA, TZA | 3 (12%) |
| Total Respondents | 15 (100%) | 26 (100%) | ||
Afghanistan, AFG; Liberia, LBR; Angola, AGO; Angola, AGO; Madagascar, MDG; Benin, BEN; Malawi, MWI; Bolivia, BOL; Mali, MLI; Brazil, BRA; Mozambique, MOZ; Burkina Faso, BFA; Nigeria, NGA; Central African Republic, CAF; Papua New Guinea, PNG; Colombia, COL; Republic of Congo, COG; Cote D'Ivoire, CIV; Rwanda, RWA; Democratic Republic of Congo, COD; Senegal, SEN; Ecuador, ECU; Swaziland, SWZ; Ethiopia, ETH; Tajikistan, TJK; Ghana, GHA; Tanzania, TZA; Haiti, HTI; Uganda, UGA; Indonesia, IDN; Union of Comoros, COM; Kenya, KEN; Uzbekistan, UZB; Korea, KOR; Zambia, ZMB; Kyrgyzstan, KGZ; Zanzibar, ZBR